Re: COVID-19 News and Discussions
Posted: Thu Jun 17, 2021 10:36 am
A community of futurology enthusiasts
https://www.futuretimeline.net/forum/
https://www.futuretimeline.net/forum/viewtopic.php?f=17&t=53
(The Conversation) While it’s now pretty easy to get a COVID-19 shot in most places in the U.S., the vaccine rollout in other parts of the world has been slow or inconsistent due to shortages, uneven access and concerns about safety.
Researchers hope that a mix-and-match approach to COVID-19 vaccines will help alleviate these issues and create more flexibility in the immunization regimens available to people.
Around the world, different pharmaceutical companies have taken different approaches to developing vaccines. Pfizer-BioNTech and Moderna created mRNA vaccines. Oxford-AstraZeneca and Johnson & Johnson went with what are called viral vectors. The Novavax COVID-19 vaccine is protein-based.
So mixing vaccines could mean more than just switching manufacturers – like from Pfizer for dose one to Moderna for dose two. You might be tapping into a different way to stimulate your immune response if you opt for a first dose of AstraZeneca and a second dose of Moderna.
The most obvious benefits of treating various brands and kinds of COVID-19 vaccine as interchangeable are logistical – people can get whatever shot is available without worry. By speeding up the global vaccination rollout, mixing and matching vaccines could help end this pandemic. Researchers also hope combining different vaccines will trigger a more robust, longer-lasting immune response compared to receiving both doses of a single vaccine. This approach may better protect people from emerging variants.
Read more: https://www.nytimes.com/2021/06/17/heal ... viral.htmlSource: New York Times
The U.S. government will invest $3.2 billion to develop antiviral pills for Covid-19, the Department of Health and Human Services announced on Thursday. Such a treatment could keep people out of the hospital and potentially save many lives in the years to come, as the virus becomes a perennial threat despite the distribution of effective vaccines. A number of other viruses, including influenza, H.I.V. and hepatitis C, can be treated with a simple pill.
But despite more than a year of research, no such drug exists for the coronavirus. Operation Warp Speed, the Trump administration’s program for accelerating Covid-19 research, invested far more money in the development of vaccines than of treatments, a gap that the new program will try to fill. The new influx of money will speed up the clinical trials of a few promising drug candidates. If all goes well, some of those pills might become available by the end of this year. The Antiviral Program for Pandemics will also support research on entirely new drugs — not just for the coronavirus, but for viruses that could cause future pandemics.
.
...................................
(Reuters) - Coronavirus-related deaths worldwide passed a grim milestone of 4 million on Thursday, according to a Reuters tally, as many countries struggle to procure enough vaccines to inoculate their populations.
While the number of new cases and deaths have abated in countries like the United States and Britain, several nations have vaccine shortages as the Delta variant becomes the dominant strain around the world.
It took over a year for the COVID-19 death toll to hit 2 million, while the next 2 million were recorded in just 166 days, according to a Reuters analysis.
The top five countries by total number of deaths – the United States, Brazil, India, Russia and Mexico – represent about 50% of all deaths in the world, while Peru, Hungary, Bosnia, the Czech Republic and Gibraltar have the highest death rates when adjusted for population. (Graphic on global cases and deaths) tmsnrt.rs/34pvUyi
---- snip ----The U.S. Embassy in Kabul says it is suffering from a major COVID-19 outbreak that has largely confined staff to their quarters and is disrupting many of its operations. Earlier this week, the embassy announced that it was suspending in-person visa interviews for Afghans who had worked for the U.S. military.
In a note sent to staff, seen by NPR, the embassy says 114 people "have COVID and are in isolation; one has died, and several have been medevaced." The note goes on to say that military hospital ICU resources are at full capacity and that the embassy has been forced to "create temporary, on-compound COVID-19 wards to care for oxygen-dependent patients." Most of the cases involve individuals who are unvaccinated or not fully vaccinated.
"We are saddened by the deaths of many valiant Afghans, who have been sickened by this pandemic and we in fact grieve the passing of an embassy local staff member," said Ned Price, the State Department's spokesperson.
The embassy requests staff to get vaccinated, stay six feet from others, suspends the use of pools and gyms, and demands strict mask compliance from staff. "Wear your masks, correctly! We are seeing a lot of noses."
(Science) GENEVA—Just a few weeks ago, the mood here at the headquarters of the World Health Organization (WHO) was still decidedly somber. WHO had pushed hard for equitable distribution of COVID-19 vaccines, yet a “grotesque” gap had formed between rich and poor nations, said WHO’s director-general, Tedros Adhanom Ghebreyesus. Whereas several rich countries had enough vaccine to start to vaccinate teenagers, who are at very low risk of becoming severely ill, nurses and doctors in Africa remained unprotected.
“Have you got anyone left to vaccinate in your places?” Bruce Aylward, a top-level WHO official asks facetiously. “Are we going to vaccinate the goldfish next?”
But a meeting of the G7, held in Cornwall, U.K., last weekend, has changed the gloomy outlook. The leaders of the seven big industrialized democracies committed to donating 1 billion doses—870 million more than previously announced—by the end of 2022. The vast majority will move through the COVID-19 Vaccines Global Access (COVAX) Facility, a nonprofit set up by WHO that Aylward is working with. COVAX has built a war chest of $9.6 billion solely for purchasing vaccine at discount prices for poor countries.
“It’s a tipping point,” Aylward says. Seth Berkley, who heads Gavi, the Vaccine Alliance—another key COVAX partner—says the new interest in helping poorer countries marks a long overdue “mindset shift.” “We’ve been talking about it from the beginning: You’re only safe if everyone’s safe,” he says. “But nobody was listening.”
There’s more good news: Vaccine manufacturers are still scaling up production, and Novavax, a U.S.-based biotech, reported stellar efficacy results for its low-cost, easy-to-store vaccine this week, further raising hopes that the gap between rich and poor can be narrowed. (Many had hoped a few hundred million more doses might come from CureVac this year, but that company yesterday reported disappointing results from an efficacy trial that may derail its candidate.)